-Next-generation sequencing of the COVID-19 virus is providing powerful metagenomic data, which, combined with clinical data, will inform the search for effective treatments, as reported in the peer-reviewed journal Pediatric Allergy, Immunology, and Pulmonology. Click here to read the article now.
“Continued genomic and epigenomic analysis of SARS-CoV-2 is critical,” say Drs. Dehority and Dinwiddie from The University of New Mexico School of Medicine, “as it can be used to determine the number of virus strains, how the virus is introduced into new regions, the number of introductions of the virus, if there is community spread of virus, if outbreaks are linked, and how the virus is evolving.”
Genetic analysis will also guide and inform efforts to develop vaccines and both novel and repurposed therapeutic agents, by testing for viral susceptibility or resistance to these interventions.
Pediatric Allergy, Immunology, and Pulmonology Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, Stony Brook University School of Medicine, states that: “As of May 25, 2020, 1,637,456 cases of COVID-19 have been reported to the Centers for Disease Control with 97,669 deaths. The use of these new techniques not only for identification but ongoing surveillance of novel viral pathogens can contribute to early strategic public health responses.”
About the Journal
Pediatric Allergy, Immunology, and Pulmonology is a quarterly, peer-reviewed journal published online with open access options and in print that synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. Led by Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook, the Journal provides comprehensive coverage to further the understanding and optimize the treatment of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a sample issue may be viewed on the Pediatric Allergy, Immunology, and Pulmonology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Breastfeeding Medicine, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 90 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.